Inhibition of STAT5a by Naa10p contributes to decreased breast cancer metastasis

Carcinogenesis

Volumn 35, Issue 10, 2014, Pages 2244-2253

  Zeng, Yan ^a,b   Min, Li ^a   Han, Yong ^a   Meng, Lin ^c   Liu, Caiyun ^a   Xie, Yuntao ^c   Dong, Bin ^c   Wang, Lixin ^c   Jiang, Beihai ^c   Xu, Huiyu ^a   Zhuang, Qing ^a   Zhao, Chuanke ^c   Qu, Like ^c   Shou, Chengchao ^a  

^a Amsterdam   (China)

^b SHIHEZI UNIVERSITY   (China)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; INTERLEUKIN 1BETA; JANUS KINASE 2; N ALPHA ACETYLTRANSFERASE 10; STAT5A PROTEIN; UNCLASSIFIED DRUG; ID1 PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF DIFFERENTIATION 1; JAK2 PROTEIN, HUMAN; NAA10 PROTEIN, HUMAN; PEPTIDE ALPHA N ACETYLTRANSFERASE A; PEPTIDE ALPHA N ACETYLTRANSFERASE E; STAT5 PROTEIN; STAT5A PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; METASTATIC BREAST CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE METASTASIS; METABOLISM; MORTALITY; PATHOLOGY;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; INTERLEUKIN-1BETA; JANUS KINASE 2; LYMPHATIC METASTASIS; METABOLIC NETWORKS AND PATHWAYS; MICE; MICE, INBRED BALB C; N-TERMINAL ACETYLTRANSFERASE A; N-TERMINAL ACETYLTRANSFERASE E; NF-KAPPA B; STAT5 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925272134     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu132     Document Type: Article

References (46)

1. Kalvik, T.V. et al. (2013) Protein N-terminal acetyltransferases in cancer. Oncogene, 32, 269-276.
2. Lim, J.H. et al. (2006) Human arrest defective 1 acetylates and activates beta-catenin, promoting lung cancer cell proliferation. Cancer Res., 66, 10677-10682.
3. Shin, D.H. et al. (2009) Arrest defective-1 controls tumor cell behavior by acetylating myosin light chain kinase. PLoS One, 4, e7451.
4. Seo, J.H. et al. (2010) Arrest defective 1 autoacetylation is a critical step in its ability to stimulate cancer cell proliferation. Cancer Res., 70, 4422-4432.
5. Fisher, T.S. et al. (2005) Analysis of ARD1 function in hypoxia response using retroviral RNA interference. J. Biol. Chem., 280, 17749-17757.
6. Wang, Z. et al. (2012) Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis. Proc. Natl Acad. Sci. USA, 109, 3053-3058.
7. Yi, C.H. et al. (2007) A genome-wide RNAi screen reveals multiple regulators of caspase activation. J. Cell Biol., 179, 619-626.
8. Arnesen, T. et al. (2006) Induction of apoptosis in human cells by RNAimediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex. Oncogene, 25, 4350-4360.
9. Hua, K.T. et al. (2011) N-a-acetyltransferase 10 protein suppresses cancer cell metastasis by binding PIX proteins and inhibiting Cdc42/Rac1 activity. Cancer Cell, 19, 218-231.
10. Kuo, H.P. et al. (2010) ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. Sci. Signal., 3, ra9.
11. Min, L. et al. (2013) N-a-acetyltransferase 10 protein is a negative regulator of 28S proteasome through interaction with PA28β. FEBS Lett., 587, 1630-1637.
12. Lee, C.F. et al. (2010) hNaa10p contributes to tumorigenesis by facilitating DNMT1-mediated tumor suppressor gene silencing. J. Clin. Invest., 120, 2920-2930.
13. Ren, T. et al. (2008) Generation of novel monoclonal antibodies and their application for detecting ARD1 expression in colorectal cancer. Cancer Lett., 264, 83-92.
14. Jiang, B. et al. (2010) Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients. Am. J. Pathol., 177, 1095-1103.
15. Midorikawa, Y. et al. (2002) Identification of genes associated with dedifferentiation of hepatocellular carcinoma with expression profiling analysis. Jpn. J. Cancer Res., 93, 636-643.
16. Huang, E. et al. (2003) Gene expression predictors of breast cancer outcomes. Lancet, 361, 1590-1596.
17. Wang, Z.H. et al. (2011) Up-regulation of human arrest-defective 1 protein is correlated with metastatic phenotype and poor prognosis in breast cancer. Asian Pac. J. Cancer Prev., 12, 1973-1977.
18. Arnesen, T. et al. (2005) Identification and characterization of the human ARD1-NATH protein acetyltransferase complex. Biochem. J., 386, 433-443.
19. Xu, H. et al. (2012) N-a-acetyltransferase 10 protein inhibits apoptosis through RelA/p65-regulated MCL1 expression. Carcinogenesis, 33, 1193-1202.
20. Perk, J. et al. (2005) Id family of helix-loop-helix proteins in cancer. Nat. Rev. Cancer, 5, 603-614.
21. Sikder, H.A. et al. (2003) Id proteins in cell growth and tumorigenesis. Cancer Cell, 3, 525-530.
22. Nieborowska-Skorska, M. et al. (2006) Id1 transcription inhibitor-matrix metalloproteinase 9 axis enhances invasiveness of the breakpoint cluster region/abelson tyrosine kinase-transformed leukemia cells. Cancer Res., 66, 4108-4116.
23. Schmidt, M. et al. (2010) Inhibitor of differentiation 1 (ID1) promotes cell survival and proliferation of prostate epithelial cells. Cell. Mol. Biol. Lett., 15, 272-295.
24. Kang, Y. et al. (2003) A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol. Cell, 11, 915-926.
25. Gumireddy, K. et al. (2009) KLF17 is a negative regulator of epithelialmesenchymal transition and metastasis in breast cancer. Nat. Cell Biol., 11, 1297-1304.
26. Xu, M. et al. (2003) STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPbeta. EMBO J., 22, 893-904.
27. Koptyra, M. et al. (2011) Signal transducer and activator of transcription 5a/b: biomarker and therapeutic target in prostate and breast cancer. Int. J. Biochem. Cell Biol., 43, 1417-1421.
28. Darnell, J.E. Jr. (1997) STATs and gene regulation. Science, 277, 1630-1635.
29. Reich, N.C. et al. (2006) Tracking STAT nuclear traffic. Nat. Rev. Immunol., 6, 602-612.
30. Tan, S.H. et al. (2008) Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr. Relat. Cancer, 15, 367-390.
31. Sultan, A.S. et al. (2005) Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene, 24, 746-760.
32. Zeng, Y. et al. (2013) Inverse correlation between Naa10p and MMP-9 expression and the combined prognostic value in breast cancer patients. Med. Oncol., 30, 562.
33. Wood, A.D. et al. (2009) ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling. Blood, 114, 1820-1830.
34. Meydan, N. et al. (1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature, 379, 645-648.
35. Pan, Z.K. et al. (1996) Bradykinin stimulates NF-kappaB activation and interleukin 1beta gene expression in cultured human fibroblasts. J. Clin. Invest., 98, 2042-2049.
36. Lee, M.N. et al. (2010) Roles of arrest-defective protein 1(225) and hypoxia-inducible factor 1alpha in tumor growth and metastasis. J. Natl Cancer Inst., 102, 426-442.
37. Miyoshi, K. et al. (2001) Signal transducer and activator of transcription (Stat) 5 controls the proliferation and differentiation of mammary alveolar epithelium. J. Cell Biol., 155, 531-542.
38. Zhu, M. et al. (1999) Functional association of Nmi with Stat5 and Stat1 in IL-2-and IFNgamma-mediated signaling. Cell, 96, 121-130.
39. Pfitzner, E. et al. (1998) p300/CREB-binding protein enhances the prolactinmediated transcriptional induction through direct interaction with the transactivation domain of Stat5, but does not participate in the Stat5-mediated suppression of the glucocorticoid response. Mol. Endocrinol., 12, 1582-1593.
40. Litterst, C.M. et al. (2003) NCoA-1/SRC-1 is an essential coactivator of STAT5 that binds to the FDL motif in the alpha-helical region of the STAT5 transactivation domain. J. Biol. Chem., 278, 45340-45351.
41. Fang, F. et al. (2009) Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells. Endocrinology, 150, 1597-1606.
42. Ogawa, S. et al. (2008) Physical and functional interactions between STAT5 and Runx transcription factors. J. Biochem., 143, 695-709.
43. Nakajima, H. et al. (2001) Functional interaction of STAT5 and nuclear receptor co-repressor SMRT: implications in negative regulation of STAT5-dependent transcription. EMBO J., 20, 6836-6844.
44. Zheng, J. et al. (2011) Negative cross talk between NFAT1 and Stat5 signaling in breast cancer. Mol. Endocrinol., 25, 2054-2064.
45. Soldaini, E. et al. (2000) DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. Mol. Cell. Biol., 20, 389-401.
46. Zitvogel, L. et al. (2012) Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol., 13, 343-351.